Bicara Therapeutics (BCAX) Set to Announce Quarterly Earnings on Monday

by · The Markets Daily

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 12:30 PM ET.

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.82). On average, analysts expect Bicara Therapeutics to post ($3.49) EPS for the current fiscal year and ($3.76) EPS for the next fiscal year.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $9.13 on Monday. Bicara Therapeutics has a one year low of $8.36 and a one year high of $30.99. The company has a market cap of $604.13 million, a P/E ratio of -2.95 and a beta of -0.32. The firm has a 50 day simple moving average of $19.74 and a two-hundred day simple moving average of $21.16.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BCAX. Mizuho lifted their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Wells Fargo & Company raised their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Wedbush reduced their price objective on Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating on the stock in a research report on Thursday. BMO Capital Markets began coverage on shares of Bicara Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $35.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.91.

View Our Latest Research Report on Bicara Therapeutics

Insider Activity at Bicara Therapeutics

In other news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the completion of the transaction, the chief executive officer directly owned 181,641 shares in the company, valued at $4,159,578.90. This trade represents a 8.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.97, for a total value of $349,625.00. Following the completion of the transaction, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,632,044.35. This represents a 8.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 58,750 shares of company stock valued at $1,554,800 in the last three months. Corporate insiders own 13.80% of the company’s stock.

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.

See Also